As of November 6, 2026, Shuttle Pharmaceuticals Holdings, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 7, 2026 (Form 8-K, May 7, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Shuttle Pharmaceuticals Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Shuttle Pharmaceuticals Holdings, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-07. Every row below is cited to the filing it comes from, and this page adds each new change as Shuttle Pharmaceuticals Holdings, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2025-11-21 (layoff filings and notices).
Also on the record for Shuttle Pharmaceuticals Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Form D, private offering | $9.96M sold | Form D page | Source |
| February 11, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| February 11, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| December 11, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| November 18, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| November 7, 2025 | Form D, private offering | $2.50M sold | Form D page | Source |
| August 5, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| June 26, 2025 | Form D, private offering | $4.25M sold | Form D page | Source |
| March 5, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 13, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| January 22, 2025 | IPO filing, Form RW | — | IPO filings | Source |
| January 15, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
Selling to them or working with them? See who runs Shuttle Pharmaceuticals Holdings, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Shuttle Pharmaceuticals Holdings, Inc. and the records around it.
Shuttle Pharmaceuticals Holdings, Inc. elsewhere on the record
- Company profile and every filing May 2026
- Form D filing May 2026
- IPO filing Feb 2026
- Layoff notices Nov 2025
- Form D filing Nov 2025
- Who owns it
Watch Shuttle Pharmaceuticals Holdings, Inc.
Get an email when Shuttle Pharmaceuticals Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Shuttle Pharmaceuticals Holdings, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Shuttle Pharmaceuticals Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Shuttle Pharmaceuticals Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-07 | Reported | not named in the filing | 8-K, 2026-05-07 |
New leaders reset buying decisions — get the Full Report on Shuttle Pharmaceuticals Holdings, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportWatch Shuttle Pharmaceuticals Holdings, Inc. (free up to 3)
Find people with the same kind of experience as the senior executive at Shuttle Pharmaceuticals Holdings, Inc., with the record behind each one.
Find candidates like senior executive at Shuttle Pharmaceuticals Holdings, Inc.Every change, in the filing's words
Reported
Appointment of Co-Chief Executive Officer On May 4, 2026, in connection with the consummation of the Merger and pursuant to the Merger Agreement, the Board of Directors of Shuttle approved the appointment of Ryan Trasolini, Chief Executive Officer of the Company, as Co-Chief Executive Officer of the Acquiror, effective at the Effective Time.
- Since 2020, Mr. Trasolini has been the founding shareholder and an active investor in Sesh Products, Inc., a Delaware corporation.
- Mr. Trasolini was also the founding shareholder and an active investor in US Bitcoin Corporation, a Delaware corporation, from 2020 until the completion of a merger of equals transaction with Hut 8 Corp, a Delaware corporation, in 2023.
- Mr. Oleh's departure is not the result of any disagreements with management or Shuttle's Board of Directors on any matter relating to Shuttle's operations, policies or practices.
Shuttle Pharmaceuticals Holdings, Inc.'s funding history
Tools for this story
Each opens in a new tab, filled in for Shuttle Pharmaceuticals Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.